Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines
EC de Baat, RL Mulder, S Armenian… - Cochrane Database …, 2022 - cochranelibrary.com
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer
receiving anthracyclines - de Baat, EC - 2022 | Cochrane Library Skip to Content Cookies Our …
receiving anthracyclines - de Baat, EC - 2022 | Cochrane Library Skip to Content Cookies Our …
[HTML][HTML] Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies
Y Octavia, CG Tocchetti, KL Gabrielson… - Journal of molecular and …, 2012 - Elsevier
The utility of anthracycline antineoplastic agents in the clinic is compromised by the risk of
cardiotoxicity. It has been calculated that approximately 10% of patients treated with …
cardiotoxicity. It has been calculated that approximately 10% of patients treated with …
[HTML][HTML] Doxorubicin induced heart failure: Phenotype and molecular mechanisms
MA Mitry, JG Edwards - IJC heart & vasculature, 2016 - Elsevier
Long term survival of childhood cancers is now more than 70%. Anthracyclines, including
doxorubicin, are some of the most efficacious anticancer drugs available. However, its use …
doxorubicin, are some of the most efficacious anticancer drugs available. However, its use …
Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management …
SE Lipshultz, MJ Adams, SD Colan, LS Constine… - Circulation, 2013 - Am Heart Assoc
1928 Circulation October 22, 2013 mental health, functional status, activity limitations,
cancerrelated pain, and cancer-related anxiety) declined moderately to severely in 44%. 5 …
cancerrelated pain, and cancer-related anxiety) declined moderately to severely in 44%. 5 …
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task …
JL Zamorano, P Lancellotti… - European heart …, 2016 - academic.oup.com
The task of developing CPG documents covers not only integration of the most recent
research, but also the creation of educational tools and implementation programmes for the …
research, but also the creation of educational tools and implementation programmes for the …
Targeting DNA topoisomerase II in cancer chemotherapy
JL Nitiss - Nature Reviews Cancer, 2009 - nature.com
Recent molecular studies have expanded the biological contexts in which topoisomerase II
(TOP2) has crucial functions, including DNA replication, transcription and chromosome …
(TOP2) has crucial functions, including DNA replication, transcription and chromosome …
How do chemotherapeutic agents damage the ovary?
S Morgan, RA Anderson, C Gourley… - Human reproduction …, 2012 - academic.oup.com
BACKGROUND Chemotherapy treatment in premenopausal women is associated with an
increased risk of premature ovarian failure (POF) but the exact mechanism through which …
increased risk of premature ovarian failure (POF) but the exact mechanism through which …
Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection
M Štěrba, O Popelová, A Vávrová… - Antioxidants & redox …, 2013 - liebertpub.com
Abstract Significance: Anthracyclines (doxorubicin, daunorubicin, or epirubicin) rank among
the most effective anticancer drugs, but their clinical usefulness is hampered by the risk of …
the most effective anticancer drugs, but their clinical usefulness is hampered by the risk of …
Cardioprotective interventions for cancer patients receiving anthracyclines
EC van Dalen, HN Caron… - … of systematic reviews, 2008 - cochranelibrary.com
Background Anthracyclines are among the most effective chemotherapeutic agents in the
treatment of numerous malignancies. Unfortunately, their use is limited by a dose …
treatment of numerous malignancies. Unfortunately, their use is limited by a dose …
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective …
SE Lipshultz, RE Scully, SR Lipsitz, SE Sallan… - The lancet …, 2010 - thelancet.com
Background Doxorubicin chemotherapy is associated with cardiomyopathy. Dexrazoxane
reduces cardiac damage during treatment with doxorubicin in children with acute …
reduces cardiac damage during treatment with doxorubicin in children with acute …